Motif Bio PLC Appointment of strategic adviser
14 Marzo 2016 - 8:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
14 March 2016
Motif Bio plc
("Motif" or the "Company")
Appointment of strategic adviser
Fulford to seek commercialisation agreements for iclaprim
outside the USA
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces the
appointment of specialist adviser The Fulford Group Ltd ("The
Fulford Group") to assist Motif in developing and implementing
strategies to commercialise iclaprim, the Company's lead antibiotic
currently in pivotal Phase 3 trials for the treatment of acute
bacterial skin and skin structure infections (ABSSSIs), in
territories outside of the USA.
The Company expects that such partnerships could provide the
Company with additional development capital in the form of upfront
payments, milestone payments and ongoing royalty fees. The
appointment of The Fulford Group, a specialist strategic adviser in
the healthcare sector, is an important step towards the
commercialisation of iclaprim.
Motif intends to commericalise iclaprim directly in the USA.
Graham Lumsden, CEO of Motif Bio, stated: "The future
commercialisation of iclaprim is a key driver of value for the
business, particularly its potential as an antibiotic treatment for
serious and life-threatening infections caused by multi-drug
resistant bacteria. Dosing has now begun in our two Phase 3
clinical trials and successful completion of these trials will
satisfy FDA and EMA requirements for regulatory approval. With
trials expected to complete in the second half of 2017, we are keen
to begin engaging with strategic partners to commercialise our lead
product candidate whilst retaining the all-important rights for
iclaprim in the US, the largest pharmaceutical market in the World.
I am confident that The Fulford Group will be instrumental in the
delivery of such partnerships."
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
David Huang (Chief Medical Officer)
Zeus Capital Limited (NOMAD &
BROKER)
Phil Walker/Dan Bate
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners Limited
(BROKER)
Patrick Claridge/ David Hignell
John Howes/ Rob Rees (Broking) +44 (0)20 7382 1100
Walbrook PR Ltd. (FINANCIAL PR +44 (0)20 7933 8780 or motifbio@walbrookpr.com
& IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio (www.motifbio.com)
Motif is a clinical-stage biopharmaceutical company,
specialising in the development of novel antibiotics that are
designed to be effective against serious and life-threatening
infections caused by multi-drug resistant bacteria. Our lead
product candidate, iclaprim, is being developed for the treatment
of the most common and serious bacterial infections such as acute
bacterial skin and skin structure infections (ABSSSI) and hospital
acquired bacterial pneumonia (HABP), including those caused by
resistant strains such as MRSA (methicillin-resistant
Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on
track to be completed in 2H17 and if approved, iclaprim could be
ready for commercialisation in 2018. The HABP trial is expected to
start 2H16.
The Company is in discussions with pharmaceutical companies and
universities to build a pipeline of innovative antibiotics
targeting Gram-positive and Gram-negative bacteria.
About The Fulford Group (www.thefulfordgroup.com)
The Fulford Group was founded by Dr. Wilder Fulford, who has
over 25 years' experience in life sciences M&A and corporate
finance, and extensive recent experience in pharmaceutical
licensing and partnering transactions. Dr. Fulford founded the
London office of Torreya Partners, a specialist life sciences
advisory firm, in 2011. Prior to that he was Head of European
Healthcare M&A at Deutsche Bank, Head of European Healthcare
Investment Banking at Bank of America, and Head of European
Healthcare, Chemicals and Basic Materials M&A at Merrill Lynch.
He began his career in New York, working for a number of years as a
venture capitalist, and then as an M&A banker at James D.
Wolfensohn Inc. and as a partner at Salomon Brothers. He has a PhD
in molecular biology from the Rockefeller University in New
York.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABFLLFQXFBBBE
(END) Dow Jones Newswires
March 14, 2016 03:01 ET (07:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024